News Releases

-- Company on Track to Report Top-Line AMPREVENCE Results in November 2019 --

Amphora NDA Resubmission Remains on Track for Q4 2019

-- Conference Call Scheduled for 11:00 a.m. EDT --

- Strategic financing to advance the commercialization of Evofem's lead asset, Amphora® -

Management to Host Conference Call at 11:00 a.m. EDT

-- Conference Call Scheduled for 11:00 a.m. EDT --

Top-line Data Expected in the Fourth Quarter of 2019

Financing to fund pre-launch commercialization activities of Amphora® (L-lactic acid, citric acid, and potassium bitartrate), a novel, investigational non-hormonal, on-demand, female contraceptive

Positive Phase 3 Amphora Results Enabling NDA Submission

-- Conference Call Scheduled for 11:00 a.m. EST --

- Company to Resubmit New Drug Application (NDA) for Amphora as Hormone-free Birth Control in Q2 2019 Based on Positive Top-line Phase 3 Study Results -

-- Company Remains on Track for AMPOWER Top-line Results in Late 2018 --

Management to Host Conference Call at 11:00 a.m. EST

- Currently 16.5M women in the U.S. are not using birth control and want to avoid pregnancy

-- Conference Call Scheduled for 11:00 a.m. EST --

-- On World Contraception Day, these U.S statistics support the continued need for new woman-controlled, non-hormonal birth control innovations. Ideally such methods would protect against pregnancy and also have other preventive indications (such as STI prevention), thus giving women better control over their sexual and reproductive health.

Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data now expected in Late 2018

-- Conference Call Scheduled for 11:00 a.m. EDT --

Trial Data Expected First Quarter 2019

STI Trial Investigates Amphora for Prevention of Urogenital Chlamydia Trachomatis Infection in Women

Commences Trading on NASDAQ Capital Market on Thursday, January 18, 2018 Under Ticker Symbol "EVFM"

EVOFEM SECURES $25.0 MILLION IN SERIES D FUNDING